about
Whole lesion quantitative CT evaluation of renal cell carcinoma: differentiation of clear cell from papillary renal cell carcinoma.[Holmium laser enucleation of the prostate as a day case surgery: prospective evaluation of the first 30 patients].Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas.Update on the medical treatment of metastatic renal cell carcinoma.Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways.Lapatinib and renal cell carcinoma.Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature.The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies.Optimal management of renal cell carcinoma in the elderly: a reviewPulmonary arterial hypertension due to an intratumoral shunt: an unexpected side effect of sunitinib.Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature.Off-Clamp versus On-Clamp Robotic Partial Nephrectomy: A Multicenter Match-Paired Case-Control Study.CT and MR imaging features of mucinous tubular and spindle cell carcinoma of the kidneys. A multi-institutional review.Microwave ablation of renal tumors: A narrative review of technical considerations and clinical results.Is Multiparametric MRI Useful for Differentiating Oncocytomas From Chromophobe Renal Cell Carcinomas?The experimental renal cell carcinoma model in the chick embryo.Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes.Comparison of 1800 Robotic and Open Partial Nephrectomies for Renal Tumors.Safety and Feasibility of Laparoscopic Nephrectomy for Big Tumors (≥ 10 cm): A Retrospective Multicentric Study.Personalized 3D printed model of kidney and tumor anatomy: a useful tool for patient education.The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery.Robotic unclamped "minimal-margin" partial nephrectomy: ongoing refinement of the anatomic zero-ischemia concept.The use of hemostatic agents does not prevent hemorrhagic complications of robotic partial nephrectomy.Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.Is there a volume-outcome relationship for partial nephrectomy?The use of partial nephrectomy: results from a contemporary national prospective multicenter study.[mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].[Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function outcome in tumors larger than 4 cm].Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux.Nephron-sparing surgery for renal tumors measuring more than 7 cm: morbidity, and functional and oncological outcomes.Clinicopathological characteristics of incidental prostate cancer discovered from radical cystoprostatectomy specimen: a multicenter French study.[Benign urachus abnormalities: embryology, diagnosis and treatments].Are warm ischemia and ischemia time still predictive factors of poor renal function after partial nephrectomy in the setting of elective indication?Overall mortality after radical nephrectomy in patients aged over 80 years with renal cancer: a retrospective study on preoperative prognostic factors.Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4-cm cutoff.Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication.Predictive value of magnetic resonance imaging determined tumor contact length for extracapsular extension of prostate cancer.MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma.Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients.
P50
Q35074682-422FF35B-96E9-46D8-90E0-1F3059387CC7Q35469461-6660B5F9-AB21-443C-960C-FFD9804CD86CQ37148031-6C5F8EBD-8DFA-4505-8D07-D352580DA335Q37165968-1F48F607-ED4C-4766-9D26-60F1F0C8FA7DQ37633006-F2ADF425-C65C-448A-8678-0075D866D66CQ38033193-63568AA6-3D8D-42C9-9671-CB6EBD33DA4CQ38071256-CC369FCB-8B10-404D-BB7A-E5B14B7340C0Q38094592-2BBBF09A-F591-40D9-B646-44152B65A66EQ38102680-F5FB5F29-CD34-470D-A5FF-3C28435FC6A1Q38671842-7AB8139F-1A9A-40B3-8AA3-14D9803DF91AQ38835750-D5CACBEA-CB38-46FC-84B9-9F89ECA76151Q38852318-80BAFEC5-D6C1-495A-BC42-8D045698B3C7Q38873590-413F4155-D91E-47AF-9329-003E92C4FF17Q39051974-151EC80B-3727-4748-A58B-6E3E4D2FA643Q39105393-8FDA4761-0655-4351-81D1-0433C501C560Q39257401-7E242B0C-B12F-40EE-8660-6A6F60F0BBB5Q39332588-37D8601E-F0ED-4627-ACEF-95A627DD4A3EQ39605521-B91EB4BA-499D-4F57-984D-FBF69B6148F1Q39994909-4901217F-5848-4725-8B9E-46855DA36FFAQ40750152-B684F735-93A7-4F22-BE2E-9AF44D6F403BQ40763585-B5E039D3-1884-412E-A555-DE5D26142439Q40838577-5FFAFDE9-174D-4DE4-8705-A50D83125809Q41143759-7719970B-F978-40C2-8A17-4FC667D57118Q41658924-E8FFF876-22C2-4BAB-93BF-407F6367E57EQ42629842-7B9D8A3E-791C-4799-96A1-2E610AEA9F57Q42650622-47CBC483-0EAF-4BC2-80FD-03F53160C348Q43086149-ADE21314-CDC2-4918-B68F-40D236C10C9BQ43412709-3B43CE9B-7806-4A98-9485-5BC6A6E4646BQ43508145-A43E5EE8-F452-42EB-862A-00FF73B50774Q43746583-0657BC5F-F4CB-45F5-9AEB-9F1E6748D377Q43914035-2BFE73C4-3C37-4B34-88AA-39C79F70F015Q44202485-ADEAD63F-630D-4B6B-BBA2-93CF05699EF4Q44295893-7A9E6DA3-10B1-4D29-A943-9B7764DF97D2Q45777284-C8ED77CB-B85F-4699-9907-04CD1F095E5DQ46033252-938B520B-28AE-4267-B41A-E16C46EBEEC9Q46060016-A9A4D81C-4B4B-433D-BCFA-92B0F1B0771DQ46078815-8D562CF7-0615-4247-B37C-0FBC901865E3Q46111473-EDC95F32-A29E-4162-9605-6DEE54126283Q46159369-BEFC0553-A05B-4C6C-9384-2B0736F11932Q46329056-BEA99D1B-8C4C-4B20-81F0-C34D9C6D145C
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-8564-1699
@en
name
Jean-Christophe Bernhard
@ast
Jean-Christophe Bernhard
@en
Jean-Christophe Bernhard
@es
Jean-Christophe Bernhard
@nl
type
label
Jean-Christophe Bernhard
@ast
Jean-Christophe Bernhard
@en
Jean-Christophe Bernhard
@es
Jean-Christophe Bernhard
@nl
prefLabel
Jean-Christophe Bernhard
@ast
Jean-Christophe Bernhard
@en
Jean-Christophe Bernhard
@es
Jean-Christophe Bernhard
@nl
P214
P106
P21
P214
P31
P496
0000-0001-8564-1699
P734
P7859
viaf-172185335